Browsing by Author Novartis Pharma AG

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)
1-Jan-2011Comparative efficacy of indacaterol 150 mu g and 300 mu g versus fixed-dose combinations of formoterol plus budesonide or salmeterol plus fluticasone for the treatment of chronic obstructive pulmonary disease - a network meta-analysisCope, Shannon; Capkun-Niggli, Gorana; Gale, Rupert; Jardim, Jose Roberto [UNIFESP]; Jansen, Jeroen P.; Mapi Values; Novartis Pharma AG; Novartis Horsham Res Ctr; Universidade Federal de São Paulo (UNIFESP)
1-Oct-2009COMPARISON of DATA AVAILABILITY and QUALITY for PHARMACOECONOMIC ANALYSIS in BRAZIL VERSUS the UNITED STATES and EUROPEAN UNION: the CASES of DIABETES & HYPERTENSIONAraujo, Gabriela Tannus Branco de [UNIFESP]; Campbell, J.; Parekh, H. H.; Fonseca, Marcelo Cunio Machado [UNIFESP]; Goncalves, L.; Incze, A.; Vincze, G.; Thompson, D.; Axia Bio Consulting; I3 Innovus; Universidade Federal de São Paulo (UNIFESP); Novartis Biociencias SA; Novartis Pharma AG
1-Jul-2013Efficacy of Sotrastaurin Plus Tacrolimus After de Novo Kidney Transplantation: Randomized, Phase II Trial ResultsRuss, G. R.; Tedesco-Silva Junior, Hélio [UNIFESP]; Kuypers, D. R.; Cohney, S.; Langer, R. M.; Witzke, O.; Eris, J.; Sommerer, C.; von Zur-Muehlen, B.; Woodle, E. S.; Gill, J.; Ng, J.; Klupp, J.; Chodoff, L.; Budde, K.; Univ Adelaide; Universidade Federal de São Paulo (UNIFESP); Katholieke Univ Leuven Hosp; Royal Melbourne Hosp; Semmelweis Univ; Univ Duisburg Essen; Royal Prince Alfred Hosp; Univ Heidelberg Hosp; Uppsala Univ; Univ Cincinnati; St Pauls Hosp; Novartis Pharmaceut; Novartis Pharma AG; Charite
1-Sep-2009FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one-yr multicenter studyTedesco-Silva, H. [UNIFESP]; Lorber, M. I.; Foster, C. E.; Sollinger, H. W.; Mendez, R.; Carvalho, D. B.; Shapiro, R.; Rajagopalan, P. R.; Mayer, H.; Slade, J.; Kahan, B. D.; FTY720A2202 Clinical Study Grp; Universidade Federal de São Paulo (UNIFESP); Yale Univ; UCI Med Ctr; Univ Wisconsin; Natl Inst Transplantat; Hosp Geral Bonsucesso; Univ Pittsburgh; Med Univ S Carolina; Novartis Pharma AG; Novartis Pharmaceut; Univ Texas Med Sch
15-Oct-2007FTY720 versus mycophenolate mofetil in de novo renal transplantation: Six-month results of a double-blind studyTedesco-Silva, Helio; Szakaly, Peter; Shoker, Ahmed; Sommerer, Claudia; Yoshimura, Norio; Schena, Francesco Paolo; Cremer, Malika; Hmissi, Abdel; Mayer, Hartmut; Lang, Philippe; FTY720 2218 Clinical Study Grp; Universidade Federal de São Paulo (UNIFESP); Med Univ Pecs; Royal Univ Hosp; Univ Heidelberg; Kyoto Prefectural Univ Med; Univ Bari; Novartis Pharma AG; Univ Paris 07
15-Aug-2011Improved Rejection Prophylaxis With an Initially Intensified Dosing Regimen of Enteric-Coated Mycophenolate Sodium in de Novo Renal Transplant RecipientsBudde, Klemens; Tedesco-Silva, Helio [UNIFESP]; Arns, Wolfgang; Shoker, Ahmed; Zeier, Martin; Klinger, Marian; Rosales, Beatriz; Walker, Rowan; Prestele, Hans; Vaidya, Soniya; Kuypers, Dirk; Charite; Universidade Federal de São Paulo (UNIFESP); Transplantat Zentrum; Univ Saskatchewan; Univ Heidelberg Hosp; Med Univ; Frente Rectorado LUZ; Royal Melbourne Hosp; Novartis Pharma AG; Novartis Inst BioMed Res; Univ Hosp Leuven
1-Nov-2013Search for New Endpoints for Clinical Trials of Immunosuppressive Drugs in Kidney TransplantationTedesco-Silva, Helio [UNIFESP]; Bernhardt, Peter; Dong, Gaohong; Escrig, Cesar; Universidade Federal de São Paulo (UNIFESP); Novartis Pharma AG; Novartis Pharmaceut
1-Jul-2013Sotrastaurin in Calcineurin Inhibitor-Free Regimen Using Everolimus in de Novo Kidney Transplant RecipientsTedesco-Silva Junior, Hélio [UNIFESP]; Kho, M. M. L.; Hartmann, A.; Vitko, S.; Russ, G.; Rostaing, L.; Budde, K.; Campistol, J. M.; Eris, J.; Krishnan, I.; Gopalakrishnan, U.; Klupp, J.; Universidade Federal de São Paulo (UNIFESP); Erasmus Univ; Univ Oslo; Inst Clin & Expt Med; Royal Adelaide Hosp; CHU Rangueil; Charite; Univ Barcelona; Royal Prince Alfred Hosp; Novartis Pharma AG; Novartis Healthcare Pvt Ltd